Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HS-10516 + lenvatinib
- Development stage
- Unknown
- Lead developer
- Hansoh Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HS-10516 + lenvatinib is a combination of HS-10516, a small molecule drug in clinical investigation, and lenvatinib, a well-established multikinase inhibitor[2][4]. The combination is currently being studied in advanced clear cell renal cell carcinoma (ccRCC) after progression on prior systemic therapy[2]. HS-10516's precise mechanism has not been fully disclosed, but it targets neoplasms and renal cell carcinoma[4]. Lenvatinib acts by inhibiting multiple receptor tyrosine kinases, including vascular endothelial growth factor receptors (VEGFR1, VEGFR2, VEGFR3), fibroblast growth factor receptors (FGFR1–4), platelet-derived growth factor receptor alpha (PDGFRα), RET, and KIT, leading to inhibition of tumor angiogenesis and proliferation[1]. The rationale for combination therapy is to leverage potential synergistic antitumor effects: HS-10516 is under dose exploration and proof-of-concept phases in ccRCC, while lenvatinib provides established kinase-inhibiting effects.
- Other names
- HS-10516 + lenvatinib
02
Targets
EPAS1 (Hypoxia-inducible factor 2-alpha)FGFR4 (Fibroblast growth factor receptor 4)PDGFRA (Platelet-derived growth factor receptor alpha)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR3 (Fibroblast growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)FGFR2 (Keratinocyte growth factor receptor)FGFR1 (Fibroblast growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on HS-10516 + lenvatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HS-10516 + lenvatinib.